Moffitt logo

Clinical Trials Search

Clinical Trial 19691

Cancer Type: Cutaneous
Interventions:Pembrolizumab (Keytruda); Placebo

Study Type: Treatment
Phase of Study: Phase III

  • Zeynep Eroglu

Call 813-745-6100
or 1-800-679-0775

Study Title

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-Risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study (Keynote 716)



To compare Recurrence-free Survival (RFS) between treatment arms. Hypothesis (H1): Pembrolizumab is superior to placebo with respect to RFS as assessed by the site investigator.

Inclusion Criteria

  • Surgically resected and histologically/pathologically confirmed new diagnosis of Stage IIB or IIC cutaneous melanoma per American Joint Committee on Cancer (AJCC) 8th edition guidelines
  • Not previously treated for melanoma beyond complete surgical resection of the current primary melanoma lesion
  • No more than 12 weeks between final surgical resection and first randomization.
  • No evidence of metastatic disease on imaging as determined by investigator
  • Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
  • Has recovered adequately from toxicity and/or complications from surgery prior to study start
  • Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
  • Female participants must not be pregnant or breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment if they are a woman of childbearing potential (WOCBP)

  • Exclusion Criteria

  • Has a known additional malignancy that is progressing or has required active antineoplastic therapy (including hormonal) within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-ulcerated primary melanoma > Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
  • Has recovered adequately from major surgery or the toxicity and/or complications from the intervention prior to starting study treatment
  • WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-Programmed Cell Death Receptor Ligand 1 (PD-L1) or anti-Programmed Cell Death Receptor Ligand 2 ( PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)
  • Has received prior systemic anti-cancer therapy for melanoma including investigational agents
  • Has received a live vaccine within 30 days prior to the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Severe hypersensitivity (≥Grade 3) to any excipients of pembrolizumab
  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • History of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Active infection requiring systemic therapy
  • Known history of human immunodeficiency virus (HIV) infection
  • Known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus (defined as Hepatitis C virus ribonucleic acid ((RNA)) [qualitative] is detected) infection
  • History of active tuberculosis (Bacillus tuberculosis)
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study starting with the screening visit through 120 days after the last dose of study treatment
  • Has had an allogeneic tissue/solid organ transplant